Newsroom

For all company announcements, please refer to SGX company disclosures page.

30

June 2020

Tuesday

iX Biopharma Ltd is pleased to announce robust uptake of Xativa™ following its launch in Australia at the end of April 2020. Its initial production runs of approximately 1700 boxes of Xativa™, a sublingual medicinal cannabidiol (“CBD”) wafer, have been fully sold.

More information can be found in the attached press release.

09

June 2020

Tuesday

iX Biopharma Ltd is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application entitled “Fast Dissolving Solid Dosage Form” (U.S. Patent Application No. 13/504,309).

More information can be found in the attached press release.

26

May 2020

Tuesday

iX Biopharma Ltd. is pleased to announce that it has commenced supply of Wafesil® and Silcap®, which are medicines for the treatment of male erectile dysfunction, through telemedicine in Australia.

More information can be found in the attached press release.

11

May 2020

Monday

Read our update on impact of COVID-19 on business operations from iX Biopharma Chairman & CEO here.

06

May 2020

Wednesday

iX Biopharma Group’s Xativa product, the world’s first medicinal cannabis sublingual wafer, has been featured on Channel 9 News Brisbane.


Watch the news feature here

Read more

04

May 2020

Monday

Entity has seen exceptional demand for its LumeniX and RestoriX nutraceutical products less than three weeks into the opening of Entity flagship stores on JD Worldwide and Tmall Global.

More information can be found in the attached press release.

29

April 2020

Wednesday

iX Biopharma inks agreement with Cannatrek to supply Xativa™, the world’s first freeze-dried sublingual medicinal cannabis wafer, to the Australian market.

More information can be found in the attached press release.

27

April 2020

Monday

iX Biopharma Ltd is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. for the licensing, supply and distribution of Wafesil™, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

More information can be found in the attached press release.

13

April 2020

Monday

iX Biopharma Ltd is pleased to announce the opening of Entity’s new flagship store on Tmall Global (“Tmall”), Alibaba Group’s cross-border B2C e-commerce platform.

More information can be found in the attached press release.

 

06

April 2020

Monday

iX Biopharma Ltd is pleased to announce the opening of the Entity flagship store on JD Worldwide, JD.com’s cross-border e-commerce platform. JD Worldwide provides a platform for Chinese consumers to purchase authentic imported products and enables international suppliers to sell directly to Chinese consumers without requiring an established presence in China.

More information can be found in the attached press release.

 

11

February 2020

Tuesday

iX Biopharma Ltd. has reported results for the second quarter and/or half yearly results as of 31 December 2019.

The second quarter financial statements for the period can be found here.

30

January 2020

Thursday

iX Biopharma Ltd has published its presentation for Phillip securities Jan 2020.

The presentation can be found here.

10

December 2019

Tuesday

iX Biopharma Ltd is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain.

More information can be found in the attached press release.

05

December 2019

Thursday

iX Biopharma Ltd is pleased to announce that it has been granted a cannabis manufacturing licence from the Office of Drug Control in Australia.

The Group has now secured all the necessary licences for its Australian TGA cGMP facility to manufacture, import and export medicinal cannabis.

More information can be found in the attached press release.

 

05

November 2019

Tuesday

iX Biopharma Ltd. has reported results for the first quarter and financial year ended 30 September 2019.

The first quarter financial statements for the period can be found here.

22

October 2019

Tuesday

iX Biopharma Ltd is pleased to announce that it has been granted a patent in India (Patent no. 319759) for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

18

October 2019

Friday

iX Biopharma Ltd is pleased to announce that at the Annual General Meeting of the Company held on 18 October 2019, all resolutions set out in the Notice of AGM dated 26 September 2019 were duly passed by way of poll vote.

The results of the Annual General Meeting can be found here.

26

September 2019

Thursday

iX Biopharma Ltd has published its Annual Report for FY2019.

The Annual Report can be found here, together with the Notice of AGM.

06

September 2019

Friday

iX Biopharma Ltd participated in SGX’s 20th anniversary celebrations by striking the SGX gong to open the Singapore securities market on 6 September 2019. The Company commemorated its milestones since listing and shared about its growth drivers and market trends impacting the healthcare industry.

Read On

23

August 2019

Friday

iX Biopharma Ltd. has reported results for the fourth financial quarter and financial year ended 30 june 2019

The fourth quarter financial statements for the period can be found here.

21

May 2019

Tuesday

iX Biopharma is pleased to announce that following the completion of its Phase 2 clinical study on Wafermine, a sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain, the U.S. Food and Drug Administration (FDA) has scheduled the End-of-Phase 2 (EOP2) meeting with the Company in the third quarter of 2019. Wafermine is the first sublingual ketamine drug seeking FDA approval for the treatment of moderate to severe acute pain, and is a Phase 2-ready drug for treatment resistant depression.

More information can be found in the attached press release.

09

May 2019

Thursday

iX Biopharma Ltd. has reported results for the third financial quarter and nine months ended 31st March 2019.

The third quarter financial statements for the period can be found here.

18

March 2019

Monday

The Board of Directors of iX Biopharma Ltd. is pleased to announce that the Company has successfully completed the sale of Chemical Analysis Pty Ltd to Eurofins Australia New Zealand Holding Pty Ltd. 

More information can be found in the attached press release

18

February 2019

Monday

The Board of Directors of iX Biopharma Ltd. wishes to announce that the Company has entered into a sale and purchase agreement with Eurofins Australia New Zealand Holding Pty Ltd (the “Purchaser”), an independent third party, on 15 February 2019 in respect of the proposed disposal of the Company’s entire shareholding interest (comprising 20 ordinary shares) in the Company’s wholly-owned subsidiary, Chemical Analysis Pty Ltd to the Purchaser. 

More information on the proposed disposal of the laboratory testing business can be found here

11

February 2019

Monday

iX Biopharma Ltd. has reported results for the second financial quarter and first half-year ended 31 December 2018 (unaudited).

The second quarter financial statements for the period can be found here.

12

November 2018

Monday

iX Biopharma Ltd. has reported results for the first quarter ended 30 September 2018 (unaudited). 

The first quarter financial statements for the period can be found here.

05

November 2018

Monday

iX Biopharma Ltd will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark. Dr Janakan Krishnarajah, iX Biopharma’s Chief Medical Officer, will be presenting the results on 6 November 2018 at 3:00pm (GMT+1).  

More information can be found in the attached press release. The presentation slides can be accessed here.

27

September 2018

Thursday

iX Biopharma Ltd has published its Annual Report for FY2018.

The Annual Report can be found here, together with the Notice of AGM

05

September 2018

Wednesday

Specialty pharmaceutical company iX Biopharma Ltd is pleased to announce the success of its Phase 2 multi-dose clinical study (“KET010”) for Wafermine, its sublingual ketamine wafer for pain management.  The results confirm Wafermine’s efficacy, safety and good tolerability in patients experiencing moderate to severe acute, post-operative pain.

Following the successful results of KET010, iX Biopharma is currently preparing for its End-of-Phase-2 (EOP2) meeting with the US Food and Drug Administration to discuss the Phase 3 Wafermine clinical trial programme. 

Beyond post-operative pain, Wafermine also opens up new possibilities in the management of procedural pain, such as burns dressing changes, in the emergency department and for pre-hospital care.

More information can be found in the attached press release. The KET010 Top-line results summary can be viewed at this link.

27

August 2018

Monday

iX Biopharma Ltd. has reported results for the fourth financial quarter ended 30 June 2018 (unaudited).

FY18 saw the Group transition from a substantially R&D-based organisation to encompass production and revenue generation.

More information can be found in the attached press release. The fourth quarter financial statements for the period can be found here.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com